These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Approaches to a vaccine against hepatitis A: development and manufacture of an inactivated vaccine. André FE J Infect Dis; 1995 Mar; 171 Suppl 1():S33-9. PubMed ID: 7876646 [TBL] [Abstract][Full Text] [Related]
5. [Antiviral vaccines]. Girard M Med Trop (Mars); 1999; 59(4 Pt 2):522-6. PubMed ID: 10901858 [TBL] [Abstract][Full Text] [Related]
6. Vaccine technology: looking to the future. Dorner F; Barrett PN Ann Med; 1999 Feb; 31(1):51-60. PubMed ID: 10219714 [TBL] [Abstract][Full Text] [Related]
7. Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats. Pasetti MF; Barry EM; Losonsky G; Singh M; Medina-Moreno SM; Polo JM; Ulmer J; Robinson H; Sztein MB; Levine MM J Virol; 2003 May; 77(9):5209-17. PubMed ID: 12692223 [TBL] [Abstract][Full Text] [Related]
8. Use of interleukin 12 to enhance the cellular immune response of swine to an inactivated herpesvirus vaccine. Zuckermann FA; Martin S; Husmann RJ; Brandt J Adv Vet Med; 1999; 41():447-61. PubMed ID: 9890035 [TBL] [Abstract][Full Text] [Related]
9. Fish vaccine antigens produced or delivered by recombinant DNA technologies. Leong JC; Anderson E; Bootland LM; Chiou PW; Johnson M; Kim C; Mourich D; Trobridge G Dev Biol Stand; 1997; 90():267-77. PubMed ID: 9270855 [TBL] [Abstract][Full Text] [Related]
10. Human vaccines. Ada GL Dev Biol Stand; 1994; 82():181-8. PubMed ID: 7958473 [TBL] [Abstract][Full Text] [Related]
11. [Old and new prescriptions for infectious diseases and the newest recipes for biomedical products in plants]. Koprowski H Arch Immunol Ther Exp (Warsz); 2002; 50(6):365-9. PubMed ID: 12549429 [TBL] [Abstract][Full Text] [Related]
12. Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. Liljeqvist S; Ståhl S J Biotechnol; 1999 Jul; 73(1):1-33. PubMed ID: 10483112 [TBL] [Abstract][Full Text] [Related]
13. Vaccines for viral diseases with dermatologic manifestations. Brentjens MH; Yeung-Yue KA; Lee PC; Tyring SK Dermatol Clin; 2003 Apr; 21(2):349-69. PubMed ID: 12757257 [TBL] [Abstract][Full Text] [Related]
14. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines. Brandler S; Tangy F Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):271-91. PubMed ID: 17869338 [TBL] [Abstract][Full Text] [Related]
15. Prospects for the eradication of infectious diseases. Stuart-Harris C Rev Infect Dis; 1984; 6(3):405-11. PubMed ID: 6377445 [TBL] [Abstract][Full Text] [Related]
16. Progress in the development of an HIV-1 vaccine. Letvin NL Science; 1998 Jun; 280(5371):1875-80. PubMed ID: 9632379 [TBL] [Abstract][Full Text] [Related]
17. The impact of new technologies on vaccines. Talwar GP; Diwan M; Razvi F; Malhotra R Natl Med J India; 1999; 12(6):274-80. PubMed ID: 10732430 [TBL] [Abstract][Full Text] [Related]
18. The impact of new technologies on vaccine development. Winther MD; Dougan G Biotechnol Genet Eng Rev; 1984; 2():1-39. PubMed ID: 6085856 [TBL] [Abstract][Full Text] [Related]
19. Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis. Viktorova EG; Khattar SK; Kouiavskaia D; Laassri M; Zagorodnyaya T; Dragunsky E; Samal S; Chumakov K; Belov GA J Virol; 2018 Sep; 92(17):. PubMed ID: 29925653 [TBL] [Abstract][Full Text] [Related]